SCHEMBL8045820

SCHEMBL8045820

Fc1cc2cn[nH]c2nc1-c1cnn2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNK O75909 2/20 0.41
CDK12 Q9NYV4 2/20 0.41
DYRK1A Q13627 1/20 0.39
EPHB3 P54753 1/20 0.38
CDK2 P24941 2/20 0.38
CCNT1 O60563 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK7 P50613 1/20 0.38
CDK9 P50750 1/20 0.38
CCNH P51946 1/20 0.38
MNAT1 P51948 1/20 0.38
PIK3CB P42338 1/20 0.37
ACVR1 Q04771 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
IGF1R P08069 4/20 0.37
CYP3A4 P08684 1/20 0.36
KCNH2 Q12809 1/20 0.36
EGFR P00533 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102417 0.81 PRMT5 (0.41) CCNKCDK12DYRK1AEPHB3CDK2
SCHEMBL3228319 0.80 TGFBR2 (0.37) EPHB3PRMT5WDR77ROCK1NPC1
SCHEMBL7954620 0.78 PRMT5 (0.39) CCNKCDK12DYRK1AEPHB3CDK2
SCHEMBL8032410 0.77 DYRK1A (0.43) CCNKCDK12DYRK1AEPHB3CDK2
SCHEMBL13099752 0.76 JAK2 (0.38) CCNKCDK12CDK2CCNT1CCNE1
SCHEMBL3111414 0.75 KHK (0.43) CCNKCDK12DYRK1AEPHB3CDK2
SCHEMBL13099768 0.75 PRMT5 (0.37) CCNKCDK12DYRK1ACDK2CCNT1
SCHEMBL8046001 0.74 JAK2 (0.42) DYRK1AACVR1IGF1RKCNH2EGFR
SCHEMBL3313922 0.72 DYRK1A (0.47) CCNKCDK12DYRK1AEPHB3CDK2
SCHEMBL8043054 0.72 EPHB3 (0.47) EPHB3PIK3CBLMNAHTTIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
WO-2009038385-A2 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 CCNK 474/4885CDK12 490/4885DYRK1A 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.